Portfolio company
Ypsilon Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops T-cell receptor mimic antibodies and bispecific T-cell engagers to treat patients with solid tumours, such as triple-negative breast and lung cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
3T Biosciences
The company develops T-cell receptor therapeutics and target identification technologies for oncology patients to treat solid tumours.
PanCancerT
This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.
Neogene Therapeutics
This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.
Epsilogen
This company develops immunoglobulin E and A based antibody therapeutics to treat patients with solid tumours and ovarian cancer.
OPS-γδ
This company develops an engineered gamma delta T cell therapy platform to treat patients with solid tumours.
LAVA Therapeutics
The company develops bispecific antibodies that engage gamma-delta T cells to treat hematological and solid cancers.
Cytospire Therapeutics
This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.